Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Author(s) -
Eva Dombi,
Andrea Baldwin,
Leigh Marcus,
Michael J. Fisher,
Brian Weiss,
AeRang Kim,
Patricia Whitcomb,
Staci Martin,
Lindsey AschbacherSmith,
Tilat A. Rizvi,
Jianqiang Wu,
Rachel Ershler,
Pamela L. Wolters,
Janet Therrien,
John Glod,
Jean B. Belasco,
Elizabeth K. Schorry,
Alessandra Brofferio,
Amy J. Starosta,
Andrea Gillespie,
Austin L. Doyle,
Nancy Ratner,
Brigitte C. Widemann
Publication year - 2016
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1605943
Subject(s) - medicine , selumetinib , neurofibromatosis , plexiform neurofibroma , neurofibromatosis type i , neurofibromin 1 , neurofibromatosis type 2 , dermatology , neurofibroma , pathology , cancer , colorectal cancer , kras
Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-mitogen-activated protein kinase (MAPK) signaling.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom